Concepedia

Author

Mark VandenBranden

Eli Lilly (United States)

Also Known As

M R Vandenbranden, M VANDENBRANDEN, M VandenBranden, M Vandenbranden, M. Vandenbranden, MARK VANDENBRANDEN, Mark R. VandenBranden, Mark VandenBranden, Mark Vandenbranden

28

Publications

3.7K

Citations

24

H-Index

30

Concepts

All Affiliations

Eli Lilly (United States)Sidney & Lois Eskenazi HospitalIndiana University – Purdue University IndianapolisMedical College of WisconsinIndiana University
MV

About

Mark VandenBranden is an author at Eli Lilly (United States) specializing in biochemistry, medicine, and liver physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Biochemistry

9

9

1.1K

2

Medicine

8

8

1.1K

3

Health Sciences

4

4

386

4

Natural Sciences

3

3

218

5

Biomolecular Engineering

1

1

45

Mark VandenBranden

×

23

Publications

3.3K

Citations

21

H-Index

YearCitations

Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).

Steven Wrighton, W. Brian, Mehmet Akif Sari,

Molecular Pharmacology

1990

403

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily

Jack Gorski, Stephen D. Hall, D. I. Jones,

Biochemical Pharmacology

1994

396

In Vitro Glucuronidation Using Human Liver Microsomes and The Pore-Forming Peptide Alamethicin

Michael B. Fisher, Kristina Campanale, Bradley L. Ackermann,

Drug Metabolism and Disposition

2000

339

Isolation and Characterization of Human Liver Cytochrome P450 2C19: Correlation between 2C19 and S-Mephenytoin 4′-Hydroxylation

Steven Wrighton, Jeffrey Stevens, Gerald W. Becker,

Archives of Biochemistry and Biophysics

1993

283

Identification of a polymorphically expressed member of the human cytochrome P-450III family.

Steven Wrighton, Barbara J. Ring, Paul B. Watkins,

Molecular Pharmacology

1989

227

Bimodal distribution of renal cytochrome P450 3A activity in humans.

Barbara D. Haehner, John Gorski, Mark VandenBranden,

Molecular Pharmacology

1996

181

Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6

Sean Ekins, Mark VandenBranden, B J Ring,

Journal of Pharmacology and Experimental Therapeutics

1998

179

Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey.

J E Sharer, Lisa A. Shipley, Mark VandenBranden,

Drug Metabolism and Disposition

1995

168

Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank

Michael B. Fisher, Mark VandenBranden, Karen A. B. Findlay,

Pharmacogenetics

2000

132

Three-Dimensional Quantitative Structure Activity Relationship Analyses of Substrates for CYP2B6

Sean Ekins, Gianpaolo Bravi, Barbara J. Ring,

Journal of Pharmacology and Experimental Therapeutics

1999

104

Page 1